Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Tenaya Therapeutics announced acceptance of multiple abstracts for presentation at the ASGCT Annual Meeting, including late-breaking data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy in adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The data cover safety, biopsy, and efficacy from two dose cohorts, w…